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Abstract
Background: Up to 85% of patients with schizophrenia demonstrate cognitive dysfunction in at least one domain.
Cognitive dysfunction plays a major role in functional outcome. It is hypothesized that addition of cognitive
training to a comprehensive psychosocial programme (OPUS) enhances both cognitive and everyday functional
capacity of patients more than the comprehensive psychosocial programme alone.
Methods: The NEUROCOM trial examines the effect on cognitive functioning and everyday functional capacity of
patients with schizophrenia of a 16-week manualised programme of individual cognitive training integrated in a
comprehensive psychosocial programme versus the comprehensive psychosocial programme alone. The cognitive
training consists of four modules focusing on attention, executive functioning, learning, and memory. Cognitive
training involves computer-assisted training tasks as well as practical everyday tasks and calendar training. It takes
place twice a week, and every other week the patient and trainer engage in a dialogue on the patient’s cognitive
difficulties, motivational goals, and progress in competence level. Cognitive training relies on errorless learning
principles, scaffolding, and verbalisation in its effort to improve cognitive abilities and teach patients how to apply
compensation strategies as well as structured problem solving techniques. At 16-week post-training and at ten-
months follow-up, assessments are conducted to investigate immediate outcome and possible long-term effects of
cognitive training. We conduct blinded assessments of cognition, everyday functional capacity and associations
with the labour market, symptom severity, and self-esteem.
Discussion: Results from four-month and ten-month follow-ups have the potential of reliably providing
documentation of the long-term effect of CT for patients with schizophrenia.
Trial Registration: Clinicaltrials.gov NCT00472862.
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Cognitive dysfunction in schizophrenia
Cognitive dysfunction plays a major role in functional
outcome in schizophrenia [1-3]. Up to 85% of patients
demonstrate cognitive dysfunction in at least one
domain, and patients’ performances on neuropsychologi-
cal tests are typically in the range of 1 ½ to 2 standard
deviations (SD) below norm [4-7]. Cognitive dysfunction
associated with schizophrenia encompasses attention
deficits, poor information processing, memory difficul-
ties, and executive dysfunction leading to difficulties in
learning and poor problem-solving abilities.
The cognitive impairments associated with schizo-
phrenia are present prior to the onset of the psychotic
symptoms of the illness, and seem to be relatively stable
over time and independent of clinical state [8]. While
antipsychotic medication may effectively reduce the clin-
ical symptoms, cognitive dysfunction remains largely
unaffected [9]. The cognitive impairments constitute a
significant challenge for the treatment of schizophrenia,
and are considered to be the greatest hindrance to psy-
chosocial and vocational rehabilitation [10-12].
Studies examining the effects of cognitive rehabilitation
Recognition of the impact of cognition on functioning
in schizophrenia has given rise to the demand for inter-
vention that directly targets cognitive dysfunction.
A Cochrane systematic review from 2000 by Hayes and
McGrath [13] included three small randomised clinical
trials, which provided no conclusive evidence for or
against cognitive training as a treatment for schizophrenia.
In 2007, a meta-analysis of 26 randomised clinical trials by
McGurk and coworkers [14] found a moderate effect of
cognitive remediation on cognition, and a small to moder-
ate effect on real-world functioning and symptoms.
The 2009 PORT working group review of psychosocial
treatments for schizophrenia [15] concludes, however,
that more research in the field of cognitive remediation
is needed before a recommendation can be offered.
Some of the shortcomings in earlier trials are short-
term programmes and a lack of long-term follow-up
examinations. The sustainability of improvements there-
fore remains an unanswered question. The variability of
outcome measures used also complicates interpretation
of findings. Thus, a consensus battery of outcome mea-
sures has been suggested by MATRICS [16] for future
trials. Many studies of cognitive training (CT) were trials
with small sample sizes, which limits the conclusions
that can be drawn from the results [17]. Likewise, the
question of generalisation is a central challenge in CT-
studies: Although Dickinson et al. [18] find improve-
ments on training tasks used in CT sessions, the effect
does not generalise to other neuropsychological tests or
functional outcomes.
There is a need for well-organised and sufficiently
large randomised clinical trials of the effect of
computer-assisted CT integrated in psychosocial rehabili-
tation. In order to examine to what extent CT improves
the psychosocial rehabilitation and facilitates new learn-
ing, improvements in the level of neuropsychological per-
formance as well as the level of everyday functional
capacity must be identified and compared [16,19,20]. As
recommended by Buchanan et al. [16], the NEUROCOM
trial employs a prospective design and includes real-life
outcome measures at both baseline, immediately after 16
weeks of training and at 10 months follow-up. By
employing CT, we seek to secure individual adaptation
and motivation through continuous evaluations and level
adjustments between patient and trainer.
Objectives
The overall objective of the NEUROCOM trial is to
accept or reject the following hypotheses:
Primary hypothesis
The effect on patients’ functional capacity in daily life of
a 16-week programme of computer-assisted CT inte-
grated in OPUS is not different from OPUS alone [for a
detailed description of the OPUS intervention see [21]],
with regard to the primary response variable of everyday
functional capacity as measured by a Danish adaptation
of the brief version of the University of California San
Diego Performance Skills Assessment (UPSA-B)[22,23].
Secondary hypotheses
The effect on patients’ cognitive functioning of a
16-week programme of computer-assisted CT integrated
in OPUS is not different from OPUS alone, with regard
to the secondary response variable of seven domains on
neuropsychological tests as recommended by MATRICS
[24,25], Trail Making B [26], and a computerised
64-card version of Wisconsin Card Sorting Test [27].
Tertiary hypothesis
The effect of a 16-week programme of computer-
assisted CT integrated in OPUS is not different from
the OPUS intervention alone in terms of patients’ asso-
ciation with the labor market and self-esteem, measured
by occupational status and Rosenberg’s Self-Esteem
Scale [28].
Methods
Randomisation
The NEUROCOM study is a randomised parallel-
group clinical trial in which participants are randomly
allocated to experimental intervention versus standard
intervention (Figure 1Flowchart of the NEUROCOM
trial. See text for further information.). The centra-
lised, stratified block-randomisation 1:1 is carried out
by Copenhagen Trial Unit (CTU) following two strati-
fication criteria: Performance level on UPSA-B (good:
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Page 2 of 9total raw score ≥ 16 or poor: total raw score < 16),
and participation in OPUS cognitive-behavioral ther-
apy (CBT) group or social skills training (SST) group
(yes or no). The generation of allocation sequence is
computerised. Allocation concealment is achieved
through centralised randomisation with a block-size
unknown to investigators.
Patients being considered for inclusion in NEURO-
COM will obtain a consecutive participant number.
Each investigator will obtain a four-digit pin code by
calling the CTU. By use of this pin code, the investigator
can call CTU and request a randomisation in NEURO-
COM. The investigator then informs about NEURO-
COM, CPR-number [for explanation see [29]], UPSA-B
Assessed for eligibility (n=235) 
Excluded  (n=118) 
iNot meeting inclusion criteria (n=69) 
i Declined to participate (n=27) 
i Insufficient comprehension of Danish 
(n=18) 
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low functioning (n=15)  
i Alcohol or substance abuse (n=9) 
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Figure 1 Flowchart of the NEUROCOM trial.
Vesterager et al. Trials 2011, 12:35
http://www.trialsjournal.com/content/12/1/35
Page 3 of 9≥ or < 16, and SST/CBT group yes/no. The CTU pro-
vides a three-digit randomisation number.
Blinding
The CTU then informs the cognitive trainers of the par-
ticipant’s name, CPR-number, randomisation number,
plus the intervention arm via fax. The cognitive trainers
inform the individual participant which intervention
programme he or she has been allocated to. The trial is
not blinded with regard to participants, cognitive trai-
ners, and OPUS teams. Blinding applies to the raters
engaged in the outcome assessment. In the follow-up
assessments, the participants are instructed in advance
not to reveal what type of intervention they have
received. Blinding also applies during data analysis, i.e.,
the randomised intervention allocation is concealed
until the statistical analyses of the data have been
completed.
Participants
Patients are recruited from OPUS, which is implemen-
ted as a standard programme for young adults with
first-episode psychosis in Copenhagen and Aarhus. The
OPUS staff recruits patients to the NEUROCOM trial.
Independent assessors interview the referred patients
and evaluate the following inclusion and exclusion
criteria.
Inclusion criteria
Participants are outpatients, aged 18-35 years, diagnosed
with first-episode psychosis or schizotypal disorder
within F2 spectrum in ICD 10 http://www.who.int/clas-
sifications/icd/en/. Participants are in a post-acute phase
of illness, have sufficient comprehension of Danish (i.e.,
do not need an interpreter), and provide written
informed consent.
Exclusion criteria
Exclusion criteria are rejection of participation, organic
disorder, or abuse of psychoactive drugs.
Interventions
Experimental intervention
Under a pilot study, a first version of a manual was
developed for a 16-week CT programme for patients
with schizophrenia [30,30].
For one hour twice a week for 16 weeks, participants
engage in computer-assisted CT plus one competence
dialogue every other week. The competence dialogues
function as bridging between CT sessions and the parti-
cipant’s development of everyday life competencies.
Training consists of four modules: the first three mod-
ules cover the areas of attention, memory, and executive
functions, and the last module focuses on the cognitive
area and related tasks, which the individual participant
prefers or needs to improve: Thus, the content of
module 4 is based on both the participant’s and the trai-
ner’s judgment.
Training contains exercises of simple attention, atten-
tion span and vigilance, planning, problem solving,
interaction-based training of working memory, and ver-
bal and visual long-term memory.
Module 1 and 2 are based on non-social cognitive
tasks on a gradually increasing level of difficulty, using
COGNIsoft computer tasks [31], whereas module 3 and
4 include practical everyday tasks. This order of mod-
ules is in keeping with the notion of a hierarchy of cog-
nitive functions [12], calling for training of elementary
attention and working memory functions before addres-
sing more complex problem-solving skills. In their
review, Twamley et al. [32] stress the importance of
directly targeting the participant’s everyday functioning.
Thus, calendar training is a vital part of this interven-
tion: a way of addressing common difficulties of
memory and planning ability by explicitly teaching com-
pensatory strategies. A recent report from a working
group of cognitive remediation trials underscores the
importance of considering individual abilities, addressing
motivation, and providing bridging facilities that allow
participants to apply newly acquired skills [33,34].
Calendar training and competence dialogues are
intended to support environmental adaptation and
transference of learning.
Training relies on errorless learning principles, scaf-
folding, and strategy-learning as recommended by
Wykes and van der Gaag [35] and van der Gaag et al.
[36]. Positive reinforcement, modeling, and verbal
instructions are widely used. Trainers describe the struc-
ture and explain the purpose of training exercises at the
beginning of every session, in order to provide a consis-
tent learning environment.
A review of cognitive rehabilitation trials underscores
the importance of possibilities for individual adjustments
[37]. CT is therefore carried out individually with con-
tinuous progress evaluation between participant and
trainer.
Trainers are occupational therapists and psychologists
at bachelor or master level with psychiatric experience.
Knowledge has been exchanged throughout the process
of the pilot study about cognitive dysfunction in schizo-
phrenia. Trainers were introduced to errorless learning
principles, and didactic instruction in the manualised
CT has been carried out at meetings during preparation
of the NEUROCOM study.
Much empirical research in psychosocial interventions
for schizophrenia has shown that training in symptom
handling, social proficiency training, and supportive pro-
visions in occupational relations can help patients to
function in their daily lives [38-47]. According to Bell
et al. [48], there is sufficient evidence that the combination
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ally occurring initiatives, has the greatest potential for
promoting outcome [see also [49,50]]. CT is therefore
added to the comprehensive psychosocial programme
OPUS.
The OPUS programme consists of affiliation with a
primary patient manager, who provides contact on a
weekly basis, involves the family, and provides the
opportunity for psychoeducation and social skills train-
ing [for further details see [51-53]]. Depending on indi-
vidual needs, patients are offered to take part in group
therapy and either social skills training (SST) or cogni-
tive-behavioral therapy (CBT). Participation in SST or
CBT can be beneficial for both cognition and everyday
functioning. To ensure comparability between the parti-
cipants in the NEUROCOM trial, we stratify participants
according to group therapy (SST/CBT) yes/no before
allocation to experimental intervention (CT) versus
standard OPUS.
Control intervention group
All participants randomised to the control group receive
the intervention usually provided in OPUS. There is no
extra effort to control for the amount of clinician con-
tact. As a meta-analysis by McGurk et al. argues, the
need for such control is questionable, since trials of cog-
nitive remediation have provided no supporting evi-
dence that more clinician contact has an effect on
improvements [14].
Assessments
The first assessment occurs before randomisation, since
information from the baseline assessment is used as
stratification variables and to validate inclusion and
exclusion criteria. At baseline, participants are adminis-
tered the clinical version of WHO Present State Exami-
nation [54] and the Danish version of National Adult
Reading Test [55,55], a widely used measure of pre-psy-
chotic IQ. All other assessments are conducted in a
fixed order at baseline, post-training, and at follow-up
10 months after inclusion, regardless of whether partici-
pants have followed the full training programme accord-
ing to the intent-to-treat principle [i.e. [56]]:
￿ Functional capacity in two domains of daily life
(finance and communication) assessed using the
Danish version of UPSA-B [22,23].
￿ Neuropsychological tests of seven cognitive
domains (see Table 1 Neuropsychological assessment
tools used in the NEUROCOM trial.).
￿ Positive and negative symptoms evaluated with
Positive and Negative Symptom Scale (PANSS, [57].
￿ Danish version of Rosenberg’s Self-Esteem Scale
[28,28].
￿ Assessment of occupational status and/or educa-
tional activities.
￿ Type and dose of antipsychotic medication (chlor-
promazine equivalents).
￿ Participation in CBT or SST group treatment.
￿ Number of psychiatric hospitalisations.
￿ Sociodemographic variables: education, living sta-
tus, economic conditions, relationships (partner,
number of close friends) and number of children.
The primary outcome, UPSA-B, is a measure of func-
tional capacity in which participants are asked to per-
form everyday tasks in two areas of functioning: the
Finance subtest requires participants to count change,
read a bill, and fill out a payment form to pay the bill.
During the Communication subtest, participants are
required to role-play an emergency call using an
unplugged telephone as well as dial a number from
memory and reschedule a doctor’s appointment. The
UPSA-B requires approximately 15 minutes to complete,
and raw scores (range 0-20) are converted into scaled
scores ranging from 0-100, with higher scores indicating
better functional capacity.
Danish adaptation of the UPSA-B
The Danish adaptation of the UPSA-B was performed by
Lone Vesterager with approval from the original author
Professor Thomas L. Patterson and his co-workers Sherry
Goldman and Brian R. Kelly via email correspondence. In
order to translate the original English version of the
UPSA-B into Danish it is required to adapt stimuli to the
Danish context. In the Finance subtest of counting change
and paying a bill, the bill was modified to look like a
Table 1 Neuropsychological assessment tools used in the
NEUROCOM trial
Domain of cognition Tests
Speed of information
processing
BACS Symbol Coding
Category Fluency
Trail Making A
Attention Continuous Performance Test - Identical Pairs
Working memory Wechsler Memory Scale-III Spatial Span
Letter-Number Sequencing
Trail Making B
Verbal learning and
memory
Hopkin’s Verbal Learning Test-Revised
Visual learning and
memory
Brief Visuospatial Memory Test-Revised
Problem-solving NAB Mazes
Wisconsin Card Sorting Test, 64-card
computerised version
Social cognition Mayer-Salovey-Caruso Emotional Intelligence
Test: Managing Emotions (MSCEIT)
Pre-psychotic IQ * Danish National Adult Reading Test (DART) *
* Only assessed at baseline.
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all currency amounts were expressed in terms of the Dan-
ish krone (which is also a decimal currency system, like
the U.S. dollar). The complexity of the amounts was
retained by keeping an equivalent number of different
coins and banknotes required for correct answers. Items
in the Communication subtest (emergency call, phone
numbers, doctor’s appointment letter) were modified to be
congruent with the local requirements. All modified items
were kept at the approximately same level of difficulty as
in the original version UPSA-B.
During the NEUROCOM trial period, a cross-national
study of functional capacity in American and Swedish
patients with schizophrenia has been published [58].
Performance on a Swedish translation of the UPSA-B
was essentially identical to that of the American sample
on the original English version, indicating that the
UPSA-B measures performance-based abilities that are
consistent across differences in culture. The authors
suggest, that adaptation of the UPSA-B may well be
practical in other Western cultures.
Sample size estimation
The power of the study is set at 90%, i.e., beta = 0.1.
Alfa is set at 0.05. The primary outcome UPSA-B con-
sists of 1-point-items, and every item has a face validity
of real-world significance, i.e. correctly performing an
emergency call or correctly remembering a scheduled
appointment. On that premise the minimal relevant dif-
f e r e n c e( M I R E D I F )i ss e ta to n ep o i n to nU P S A - Bt o t a l
score (Mean = 17.63 points, SD = 1.66) [23,59]. We
assumed the SD to be 1.66. To be able to detect a dif-
ference of one point on UPSA-B mean total score
between the two groups, the required number of partici-
pants in each group is 31 or 62 in total. Estimated drop-
out of 45% necessitates recruitment of about 120
participants, 60 in each intervention group.
Ethical considerations and informed consent
The NEUROCOM trial has been approved by the Dan-
ish Ethics Committee (KF 01 300017) and the Danish
Data Protection Agency, and the trial has been regis-
tered at http://www.clinicaltrials.gov (NCT00472862)
before inclusion of the first participant. The interven-
tions and methods of investigation involve no known
physical or mental risks. Participation is voluntary and
written informed consent is obtained. All participants
are informed both verbally and in written form that they
can withdraw from the trial at any time, without it hav-
ing any consequences for their continued treatment.
Statistical analysis
Continuous outcome measures will be analysed with
repeated measurements in a mixed-effects model and
performed using SPSS 17.0. Logistic regression analyses
will be applied with binary outcome measures. Dosage
of antipsychotic medication (in chlorpromazine equiva-
lents) will be included as a covariate variable in the ana-
lyses. Dropout analysis will be carried out, comparing
baseline values for participants who drop out of inter-
vention with those who follow the entire intervention.
Baseline values of measures will be included in the ana-
lyses whenever possible.
Data sets on non-completing participants will be
included in the data analyses on an intention-to-treat
basis. In case of non-existent outcome measures (with-
drawal, dropout, lost to follow-up), the pattern of miss-
ing data and the assumption of missing data at random
(MAR) will be explored. If data distribution is skewed,
repeated-measurements analyses will be performed.
The primary outcome measure, performance on
UPSA-B, will be analysed, like other continuous out-
come measures, in a repeated-measurements model with
unstructured variance matrix. This approach assumes
that the distribution of missing data can be estimated
from the information from previous interviews and from
information about other patients in the database. The
condition for using this method is the assumption that
data are missing at random when taking into considera-
tion the information extracted from baseline interviews
and information about the other patients in the data-
base. In this model, baseline values of the scales are
included [60,61]. Variables included as covariates will be
site (Aarhus/Copenhagen), level of education, pre-
psychotic IQ (DART), baseline values of secondary
verbal memory, and the baseline values of variables that
differ significantly in dropout analyses.
Discussion
The NEUROCOM trial has several strengths in its
design. First, it is a multi-centre trial. The CT interven-
tion is integrated in treatment-as-usual at two clinical
sites, and the realistic settings of interventions increase
the external validity of the trial. Second, we employ cen-
tral randomisation, which ensures adequate allocation
concealment and observer-blinded assessment of out-
comes [62]. Third, clinically relevant outcome measures
of cognition and everyday functioning are chosen for
the assessment battery in order to ensure that any find-
ings of cognitive improvement will express positive
changes in real-life functioning. Fourth, results from
four-month and ten-month follow-ups have the poten-
tial of reliably providing documentation of the long-
term effect of CT and thus evaluating the costs and ben-
efits of extending CT for patients with schizophrenia to
clinical practice.
Furthermore, a few hallmarks of the NEUROCOM
intervention method are worth mentioning: First, the
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encouraging results [63,63]. Second, the NEUROCOM
CT programme has initiated so-called competence dia-
logues as a new initiative to bridge the gap between
laboratory cognitive exercises and everyday skills. Com-
petence dialogues are semi-structured interviews to
identify strengths and difficulties of the individual parti-
cipant, and constitute a built-in evaluation of training
progress and learning throughout the CT programme.
The limitations of the trial are related to the design:
Participants receiving long, 2-3 hour CT sessions every
week might reduce their degree of participation in OPUS
treatment-as-usual due to the intensity of the 16-week
CT programme. This means that the CT cannot truly be
an ‘add-on’ intervention to treatment-as-usual, but must
be integrated in treatment-as-usual in practice, in order
to reduce the intensity of treatment-as-usual. And as
mentioned above, there is no control condition to
account for the amount of time with personal contact
with a trainer. This may confound the results of the trial.
As the control intervention is a comprehensive psy-
chosocial programme that provides intensive support
and alleviation [e.g. [53]], it is likely to influence cogni-
tion in a positive manner. Such an indirect effect on
cognition increases the risk of not being able to discern
which improvements stem from the CT intervention. It
is also possible that the OPUS programme is an optimal
intervention and thereby forms a ceiling effect.
The trial will provide cognitive profile-results accord-
ing to seven separate domains in a relatively large Dan-
ish sample of first-episode schizophrenia, and contribute
with valuable normative data on the UPSA-B. Further-
more, the NEUROCOM results will provide an opportu-
nity to examine the association between first-episode
patients’ levels of cognitive functioning and daily life
functioning, including investigation of characteristics
necessary to benefit from CT. The NEUROCOM trial
results are expected to be published during 2011.
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